TXN and cancer: In conclusion, our results indicate that ROS1 inhibition through the administration of either crizotinib or entrectinib compromised cancer treatment outcomes by blunting oxidative stress-related DNA damage through the stimulation of the FAK-YAP-TRX signaling pathway.